EGFR Antibody-supplemented TPF-Chemotherapy. Preclinical Investigations to a Novel Approach for Head and Neck Cancer Induction Treatment

Anticancer Research

Volumn 23, Issue 6 C, 2003, Pages 4789-4795

  Knecht, Rainald ^a,b   Peters, Silke ^a   Solbach, Christine ^a   Baghi, Mehran ^a   Gstötfner, Wolfgang ^a   Hambek, Markus ^a  

^a GOETHE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Antibody; EGFR; Polychemotherapy; Squamous cell carcinoma

Indexed keywords

CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; FLUOROURACIL; MONOCLONAL ANTIBODY; TAXANE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER REGRESSION; CARCINOGENESIS; CONTROLLED STUDY; DOSE RESPONSE; DRUG POTENTIATION; DRUG RECEPTOR BINDING; HEAD AND NECK CANCER; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; NUDE MOUSE; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR GROWTH;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; CISPLATIN; DISEASE MODELS, ANIMAL; FLUOROURACIL; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; RECEPTOR, EPIDERMAL GROWTH FACTOR; TAXOIDS; TONGUE NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 0842311664     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. De Andres L, Brunet J, Lopez-Pousa A et al: Randomized trial of neoadjuvant cisplatin and fluorouracil versus carboplatin and fluorouracil in patients with stage IV-M0 head and neck cancer. J Clin Oncol 13: 1493-1500, 1995.
2. Haddad R, Tishler RB, Norris CM, Mahadevan A, Busse P, Wirth L, Goguen LA, Sullivan CA, Costello R, Case MA and Posner MR: Docetaxel, cisplatin, 5-fluorouracil (TPF)-based induction chemotherapy for head and neck cancer and the case for sequential, combined-modality treatment. Oncologist 8(1): 35-44, 2003.
3. Knecht R, Baghi M, Hambek M, Tesch H and Gstoettner W: Response rate and outcome of a novel induction chemotherapy regimen (TPF) in the first-line therapy of advanced head and neck carcinomas (SCCHN). Proc ASCO 22: 50, 2003.
4. Fan Z, Baselga J, Masui H and Mendelsohn J: Antitumor effect of anti-epidermal growth factor receptor monoclonal antibodies plus cis-diamminedichloroplatinum on well-established A431 cell xenografts. Cancer Res 53: 4637-4642, 1993.
5. Bier H, Hoffmann T, Hauser U, Wink M, Ochler M, Kovar A, Muser M and Knecht R: Clinical trial with escalating doses of the antiepidermal growth factor receptor humanized monoclonal antibody EMD 72 000 in patients with advanced squamous cell carcinoma of the larynx and hypopharynx. Cancer Chemother Pharmacol 47(6): 519-24, 2001.
6. Ford AC and Grandis JR: Targeting epidermal growth factor receptor in head and neck cancer. Head Neck 25(1): 67-73, 2003.
7. Hambek M, Solbach C, Schnuerch HG, Roller M, Stegmueller M, Sterner-Kock A, Kiefer J and Knecht R: Tumor necrosis factor alpha sensitizes low epidermal growth factor receptor (EGFR)-expressing carcinomas for anti-EGFR therapy. Cancer Res 61(3): 1045-9, 2001.
8. Veterans Affairs Laryngeal Cancer Study Group: Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. N Engl J Med 324: 1685-1690, 1991.
9. Kraus DH, Pfister DG, Harrison LB, Shah JP, Spiro RH, Armstrong JG, Fass DE, Zelefsky M, Schantz SP, Weiss MH et al: Larynx preservation with combined chemotherapy and radiation therapy in advanced hypopharynx cancer. Otolaryngol Head Neck Surg 111(1): 31-7, 1994.
10. Lefebvre JL, Chevalier D, Luboinski B et al: Larynx preservation in pyriform sinus cancer: preliminary results of a European Organization for Research and Treatment of Cancer phase III trial. J Natl Cancer Inst 88: 890-898, 1996.
11. Posner MR and Lefebvre JL: Docetaxel induction therapy in locally advanced squamous cell carcinoma of the head and neck. Br J Cancer 88(1): 11-7, 2003.
12. Schmiegel W, Schmielau J, Henne-Bruns D, Juhl H, Roeder C, Buggisch P, Onur A, Kremer B, Kalthoff H and Jensen EV: Cytokine-mediated enhancement of epidermal growth factor receptor expression provides an immunological approach to the therapy of pancreatic cancer. Proc Natl Acad Sci USA 94: 12622-12626, 1997.
13. Yang X-D, Jia X-C, Corvalan JRF, Wang P, Davis CG and Jakabovits A: Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res 59: 1236-1243, 1999.
14. Baselga J, Norton L, Albanell J, Kim Y-M and Mendelsohn J: Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825-2831, 1998.
15. Modjtahedi H, Affleck K, Stubberfield C and Dean C: EGFR blockade by tyrosine kinase inhibitor or monoclonal antibody inhibits growth, directs terminal differentiation and induces apoptosis in the human squamous cell carcinoma HN5. Int J Oncol 13: 335-342, 1998.
16. Modjtahedi H, Eccles SA, Box G, Styles J and Dean CJ: Antitumor activity of combinations of antibodies directed against different epitopes on the extracellular domain of the human EGFR receptor. Cell Biophys 22: 129-146, 1993.
17. Mujoo K, Donato NJ, Lapushin R, Rosenblum MG and Murray JL: Tumor necrosis factor ct and γ-interferon enhancement of anti-epidermal growth factor receptor monoclonal antibody binding to human melanoma cells. J Immunother 13: 166-174, 1993.
18. Baselga J, Trigo JM, Bourhis J, Tortochaux J, Cortes-Funes H, Hitt R, Gascon P, Muesser M, Harstrick A and Eckardt A: Cetuximab (C225) plus cisplatin/carboplatin is active in patients (pts) with recurrent/metastatic squamous cell carcinoma of the head and neck (SCCHN) progressing on a same dose and schedule platinum-based regimen. Proc ASCO 21: 900, 2002.
19. Sirotnak FM, Zakowski MF, Miller VA, Scher HI and Kris MG: Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6(12): 4885-92, 2000.
20. Mendelsohn J: The epidermal growth factor receptor as a target for cancer therapy. Endocr Relat Cancer 8(1): 3-9, 2001.